Integra LifeSciences (NASDAQ:IART) Hits New 12-Month Low – Time to Sell?

Integra LifeSciences Holdings Corporation (NASDAQ:IART)’s share price reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $9.76 and last traded at $9.84, with a volume of 162372 shares changing hands. The stock had previously closed at $10.39.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Wall Street Zen lowered shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Saturday. Wells Fargo & Company lowered their target price on Integra LifeSciences from $13.00 to $12.00 and set an “equal weight” rating for the company in a research note on Friday, February 27th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Integra LifeSciences in a report on Monday, December 29th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Integra LifeSciences currently has a consensus rating of “Reduce” and a consensus target price of $14.80.

Integra LifeSciences Price Performance

The business’s 50 day simple moving average is $11.72 and its 200-day simple moving average is $13.06. The stock has a market capitalization of $758.36 million, a price-to-earnings ratio of -1.45 and a beta of 1.02. The company has a quick ratio of 1.46, a current ratio of 2.54 and a debt-to-equity ratio of 1.66.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings results on Thursday, February 26th. The life sciences company reported $0.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.04. Integra LifeSciences had a positive return on equity of 14.76% and a negative net margin of 31.58%.The company had revenue of $434.93 million for the quarter, compared to analyst estimates of $429.62 million. During the same quarter last year, the company posted $0.97 EPS. The company’s revenue for the quarter was down 1.7% compared to the same quarter last year. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. On average, research analysts forecast that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current year.

Hedge Funds Weigh In On Integra LifeSciences

Several large investors have recently modified their holdings of the business. Global Retirement Partners LLC bought a new stake in shares of Integra LifeSciences in the 4th quarter valued at about $25,000. GAMMA Investing LLC raised its holdings in Integra LifeSciences by 55.3% during the third quarter. GAMMA Investing LLC now owns 2,565 shares of the life sciences company’s stock worth $37,000 after buying an additional 913 shares during the last quarter. Osaic Holdings Inc. boosted its stake in Integra LifeSciences by 36.6% during the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after purchasing an additional 1,104 shares during the last quarter. EMC Capital Management purchased a new stake in Integra LifeSciences in the 2nd quarter valued at $75,000. Finally, Tower Research Capital LLC TRC grew its position in Integra LifeSciences by 595.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock worth $98,000 after purchasing an additional 6,814 shares in the last quarter. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.